COGT
Cogent Biosciences, Inc.
Stock
$31.02−0.57 (−1.80%)Close Oct 2, 2026
Income statement
| Line | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|
| Revenue | $7.9M | $22M | $9.7M | $8.4M |
| R&D | $26M | $44M | $38M | $30M |
| Operating income | −$82M | −$32M | −$36M | −$26M |
| Net income | −$75M | −$32M | −$35M | −$25M |
| Diluted EPS | −$16.17 | −$4.18 | −$5.56 | −$10.04 |
| Diluted shares | 11.1M | 7.6M | 6.2M | 2.55B |
| Revenue growth | −65.0% | +131.1% | +16.4% | — |
| Operating margin | −1,044.3% | −143.0% | −369.9% | −312.8% |
| Net margin | −950.4% | −141.5% | −354.8% | −304.9% |